Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on developing novel oncology therapies, has announced its plans to release its second quarter 2024 financial results. The company will report these results after the U.S. financial markets close on Thursday, August 8, 2024. Following the release, Oncternal's management team will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the financial results in detail. Investors and interested parties can access the live webcast through the company's investor relations website at investor.oncternal.com. The webcast will remain archived on the site for a minimum of 30 days for those unable to attend the live event.
Oncternal Therapeutics (Nasdaq: ONCT), una azienda biofarmaceutica in fase clinica concentrata nello sviluppo di terapie oncologiche innovative, ha annunciato i suoi piani per pubblicare i risultati finanziari del secondo trimestre 2024. L'azienda comunicherà questi risultati dopo la chiusura dei mercati finanziari statunitensi, in data giovedì 8 agosto 2024. Dopo la pubblicazione, il team di gestione di Oncternal ospiterà un webcast alle 14:00 PT (17:00 ET) per fornire un aggiornamento aziendale completo e discutere in dettaglio i risultati finanziari. Gli investitori e le parti interessate possono accedere al webcast dal sito web delle relazioni con gli investitori dell'azienda all'indirizzo investor.oncternal.com. Il webcast rimarrà archiviato sul sito per un minimo di 30 giorni per coloro che non possono partecipare all'evento dal vivo.
Oncternal Therapeutics (Nasdaq: ONCT), una empresa biofarmacéutica en etapa clínica enfocada en desarrollar nuevas terapias oncológicas, ha anunciado sus planes para publicar sus resultados financieros del segundo trimestre de 2024. La empresa dará a conocer estos resultados después de que cierren los mercados financieros de EE. UU. el jueves 8 de agosto de 2024. Tras la publicación, el equipo directivo de Oncternal llevará a cabo un webcast a las 2:00 p.m. PT (5:00 p.m. ET) para proporcionar una actualización empresarial completa y discutir los resultados financieros en detalle. Los inversores y interesados pueden acceder al webcast en vivo a través del sitio web de relaciones con inversores de la empresa en investor.oncternal.com. El webcast permanecerá archivado en el sitio durante un mínimo de 30 días para aquellos que no puedan asistir al evento en vivo.
온크터널 테라퓨틱스(Nasdaq: ONCT)는 임상 단계의 생물의약품 회사로서 새로운 종양학 치료 개발에 주력하고 있으며, 2024년 2분기 재무 결과 발표 계획을 발표했습니다. 이번 결과는 2024년 8월 8일 목요일 미국 금융 시장 폐장 후에 발표됩니다. 발표 이후, 온크터널 경영진은 오후 2시 PT (오후 5시 ET)에 비즈니스 업데이트를 제공하고 재무 결과를 상세히 논의하기 위한 웹캐스트를 개최합니다. 투자자 및 관심 있는 당사자는 회사의 투자자 관계 웹사이트인 investor.oncternal.com을 통해 생중계 웹캐스트에 접근할 수 있습니다. 웹캐스트는 생중계를 참석할 수 없는 분들을 위해 최소 30일 동안 사이트에 아카이브됩니다.
Oncternal Therapeutics (Nasdaq: ONCT), une entreprise bio-pharmaceutique en phase clinique axée sur le développement de nouvelles thérapies oncologiques, a annoncé ses plans pour publier ses résultats financiers du deuxième trimestre 2024. L'entreprise présentera ces résultats après la fermeture des marchés financiers américains le jeudi 8 août 2024. Suite à cette publication, l'équipe de direction d'Oncternal animera un webcast à 14h00 PT (17h00 ET) pour fournir une mise à jour complète sur l'entreprise et discuter des résultats financiers en détail. Les investisseurs et les parties intéressées peuvent accéder au webcast en direct via le site web des relations avec les investisseurs de l'entreprise à l'adresse investor.oncternal.com. Le webcast sera archivé sur le site pour un minimum de 30 jours pour ceux qui ne peuvent pas assister à l'événement en direct.
Oncternal Therapeutics (Nasdaq: ONCT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger Onkologie-Therapien konzentriert, hat seine Pläne für die Veröffentlichung der Finanzergebnisse des zweiten Quartals 2024 bekannt gegeben. Das Unternehmen wird diese Ergebnisse nach Schluss der US-Finanzmärkte am Donnerstag, den 8. August 2024 bekannt geben. Nach der Veröffentlichung wird das Management-Team von Oncternal um 14:00 Uhr PT (17:00 Uhr ET) ein Webcast veranstalten, um ein umfassendes Geschäftsupdate zu geben und die Finanzergebnisse im Detail zu besprechen. Investoren und Interessierte können das Live-Webcast über die Investor-Relations-Website des Unternehmens unter investor.oncternal.com abrufen. Das Webcast wird für mindestens 30 Tage auf der Website archiviert, damit diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, darauf zugreifen können.
- None.
- None.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets close on Thursday, August 8, 2024. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s financial results.
The live webcast of the call will be available online at investor.oncternal.com and will be archived there for at least 30 days.
About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. ONCT-534 is an investigational dual-action androgen receptor inhibitor (DAARI) with demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR aberration. It is a potential treatment for patients with mCRPC with unmet medical need because of resistance to androgen receptor pathway inhibitors, including those with AR amplification, mutations in the AR ligand binding domain (LBD), or splice variants with loss of the AR LBD. Study ONCT-534-101 (NCT05917470) has completed enrollment and dosing in six dose cohorts for the treatment of patients with mCRPC. ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using the binding domain from zilovertamab. ONCT-808 has demonstrated activity in preclinical models against multiple hematological malignancies and solid tumors and has been shown to be specific for cancer cells expressing ROR1. Oncternal has developed a robust and reproducible manufacturing process that has the potential to reduce the time patients must wait for their individual CAR T therapy to be produced, compared with currently approved CAR T products. Oncternal has dosed patients under Study ONCT-808-101 (NCT05588440) with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of ROR1. Zilovertamab has been evaluated in a Phase 1/2 Study CIRM-0001 (NCT03088878) in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL), which resulted in
Contact Information:
Investors
Richard Vincent
858-434-1113
rvincent@oncternal.com
Media
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
FAQ
When will Oncternal Therapeutics (ONCT) report its Q2 2024 financial results?
What time is Oncternal Therapeutics' (ONCT) Q2 2024 earnings webcast scheduled for?
Where can I access Oncternal Therapeutics' (ONCT) Q2 2024 earnings webcast?
What will be discussed during Oncternal Therapeutics' (ONCT) Q2 2024 earnings call?
